VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival - - ...

Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment Full enrollment expected by Q2 2026 with plans to seek early approval at that time ...

ProstACT Global is trialling a promising new treatment option for prostate cancer, which is the most ... encouraging results in previous Phase 1 and 2 trials. There remains significant unmet ...

A new paper in the Journal of the National Cancer ... for phase 3 trials, where the odds are probably more like 1 in 3," Kimmelman continued. The paper, "Proportion of Patients in Phase 2 Oncology ...

Confirmatory Phase 3 Trial Designed to Support Commercialization of Multikine for Head and Neck Cancer Treatment Full enrollment expected by Q2 2026 with plans to seek early approval at that ... the ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

Proportion increases when considering off-label use but drops when considering drugs with substantial clinical benefit.

Patients enroll in phase 2 oncology trials seeking access to promising new treatments, but the risk-benefit assessments and ...

HealthDay News — One in 6 patients in phase 2 clinical cancer trials receives treatments ... increased to 19.4% but decreased to 9.3% for FDA-approved regimens that are considered of substantial ...